[Comparative pharmacokinetics of erythromycin target cell-associated transport and intravenous administration in patients with pneumonia]
Abstract:
The method of cell-associated antibiotic therapy consists of extracorporal exposure of the autoblood formed elements to antibiotic solution followed by their reinfusion. Pharmacokinetics of erythromycin after its intravenous and cell-associated administration in patients with community-acquired pneumonia and the clinical efficacy of the method were evaluated. HPLC of the erythromycin pharmacokinetic pattern in 20 patients showed that after the antibiotic target transport the pharmacokinetic model changed from one-compartment to two-compartment one and the antibiotic maximum concentration and elimination rate were lower vs. the intravenous administration. It was also shown that the clinical efficacies of the erythromycin intravenous administration and target transport did not significantly differ, whereas after the cell-associated transport of the antibiotic the therapeutic effect was observed earlier and the side effects were less frequent.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Dosage Interval and Administration Route: Determination Methods
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Estimation of k and VD of Aminoglycosides

